Biomarkers for hepatocellular carcinoma

Clinical Journal of Gastroenterology

Volumn 5, Issue 3, 2012, Pages 177-182

  Shiota, Goshi ^a   Miura, Norimasa ^b  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Biomarker; Early detection; Hepatocellular carcinoma; Monitoring; Prognosis

Indexed keywords

ALPHA FETOPROTEIN; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; GLYPICAN 3; TELOMERASE REVERSE TRANSCRIPTASE; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

CANCER RECURRENCE; CANCER STAGING; CHRONIC LIVER DISEASE; HEPATITIS B; HEPATITIS C; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVIEW;

EID: 84863715709     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-012-0301-x     Document Type: Review

References (72)

1. Aravalli RN, Steer CJ, Cressman ENK. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047-63.
2. Hashimoto E, Tokushige K. Hepatocellular carcinoma in nonalcoholic steatohepatitis: growing evidence of an endemic? Hepatol Res. 2012;42:1-14.
3. Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology. 2008;51:34-41.
4. Duffy MJ. Clinical uses of tumor markers: a critical review. Crit Rev Clin Lab Sci. 2001;38:225-62.
5. Thomas CMG, Sweep CGJ. Serum tumor markers: past, state of the art and future. Int J Biol Markers. 2001;16:73-86.
6. Cummings J, Ward TH, Dive C. Fit-for-purpose biomarker method validation in anticancer drug development. Drug Discov Today. 2010;15:816-25.
7. Zerhouni E. Medicine. The NIH roadmap. Science. 2003;302: 63-72.
8. McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res. 2009;15: 1898-905.
9. Malaguarnera G, Giordano M, Paladina I, Berretta M, Cappellani A, Malaguarnera M. Serum markers of hepatocellular carcinoma. Dig Dis Sci. 2010;55:2744-55.
10. Sun S, Lee NPY, Poon RTP, Fan S-T, He QY, Lau GK, Luk JM. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int. 2007;27: 1021-38.
11. Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956;8: 174.
12. Abelev GI. Production of embryonal serum alpha-globulin by hepatomas: review of experimental and clinical data. Cancer Res. 1968;28:1344-50.
13. Yoshima H, Mizuochi T, Ishii M, Kobata A. Structure of the asparagine-linked sugar chains of alpha-fetoprotein purified from human ascites fluid. Cancer Res. 1980;40:4276-81.
14. Stefanik P, Cianciara J, Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol. 2010;16:418-24.
15. Terentiev AA, Moldpgazieva NT. Structural and functional mapping of alpha-fetoprotein. Biochemistry (Mosc). 2006;71: 120-32.
16. Mizejewski GJ. Biological role of alpha-fetoprotein in cancer: prospects for anticancer therapy. Expert Rev Anticancer Ther. 2002;2:709-35.
17. Saffroy R, Pham P, Reffas M, Takka M, Lemoine A, Debuire B. New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin Chem Lab Med. 2007;45:1169-79.
18. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol. 2006;12:1175-81.
19. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, et al. Des-gamma-carboxy prothrombin and alphafetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010;138:493-502.
20. Tremolda R, Benevegnu L, Drago C, Casarin C, Cechetto A, Realdi G, Ruol A. Early detection of hepatocellular carcinoma in patients with cirrhosis by alphafetoprotein, ultrasonography and fine-needle biopsy. Hepatogastroenterology. 1989;36:519-21.
21. Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011;35:521-30.
22. Yuen M-F, Lai C-L. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol. 2005;19:91-9.
23. Taketa K, Sekiya C, Namiki M, Akamatsu K, Ohta Y, Endo Y, Kosaka K. Lectin-reactive profiles of alpha-fetoproteins characterizing hepatocellular carcinoma and related conditions. Gastroenterology. 1990;99:508-18.
24. Aoyagi Y, Suzuki Y, Isemura M, Nomoto M, Sekine C, Igarashi K, Ichida F. The fucosylation index of alpha-fetoprotein and its usefulness in the early diagnosis of hepatocellular carcinoma. Cancer. 1988;61:769-74.
25. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology. 1990;12:1420-32.
26. Kumada T, Nakano S, Takeda I, Kiriyama S, Sone Y, Hayashi K, Katoh H, Endoh T, Sassa T, Satomura S. Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol. 1999;30:125-30.
27. Yamashita F, Tanaka M, Satomura S, Tanikawa K. Prognostic significance of lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinoma. Gastroenterology. 1996;111:996-1001.
28. Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Miyata A, Shimizu H, Satomura S. Usefulness of measurement of lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol. 1999;94: 3028-33.
29. Suttie JW. Vitamin K-dependent carboxylase. Annu Rev Biochem. 1985;54:459-77.
30. Naraki T, Kohno N, Saito H, Fujimoto Y, Ohhira M, Morita T, Kohgo Y. Gamma-carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin. Biochem Biophys Acta. 2002;1586:287-98.
31. Inagaki Y, Tang W, Makuuchi M, Hasegaw K, Sugawara Y, Kokudo N. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-c-carboxyprothrombin. Liver Int. 2011;31:22-35.
32. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Watanabe K, Magario N, Yokoo T, Naraki T. Measurement of serum levels of des-gamma- carboxyprothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer. 1999;85:812-8.
33. Tang W, Miki K, Kokudo N, Sugawara Y, Imamura H, Minagawa M, Yuan LW, Ohnishi S, Makuuchi M. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma. Int J Oncol. 2003;22:969-75.
34. Koike Y, Shiratori Y, sato S, obi S, Teratani T, Imamura M, Yoshida H, Shiina S, Omata M. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561-9.
35. Khan KN, Yatsuhashi H, Yamasaki K, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection. J Hepatol. 2000;32:269-78.
36. Nagaoka S, Yatsuhashi H, Hamada H, Yano K, Matsumoto F, Daikoku M, Arisawa K, Ishibashi H, Koga M, Sata M, Yano M. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer. 2003;98:2671-7.
37. Weitz IC, Liebman HA. Dex-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma. Hepatology. 1993;18: 990-7.
38. Grazi GL, Mazziotti A, Legnani C, Jovine E, Miniero R, Gallucci A, Gozzetti G. The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the desgamma- carboxy prothrombin. Liver Transpl Surg. 1995;1:249-55.
39. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Tovota T, Takahashi T, Kasukawa R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000;95:1036-40.
40. Fujiyama S, Tanaka M, Maeda S, Ashihara H, Hirata R, Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002;62: 57-63.
41. Shimauchi Y, Tanaka M, Kuromatsu R, Oagata R, Tateishi Y, Ono N, Yutani S, Nagamatsu H, matsugaki S, Yamasaki S, Tanikawa K, Sata M. A simultaneous monitoring of lens culinaris agglutinin A-reactive alpha-fetoprotein and des-gamma-carboxy prothrombin as an early diagnosis of hepatocellular carcinoma in the follow-up of cirrhotic patients. Oncol Rep. 2000;7:249-56.
42. Filmus J, Church J, Buick RN. Isolation of a cDNA corresponding to a developmentally regulated transcript in rat intestine. Mol Cell Biol. 1988;8:4243-9.
43. Song HH, Shi W, Filmus J. OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J Biol Chem. 1997;272:7574-7.
44. Reich-Slotky R, Bonneh-Barkay D, Shaoul E, Bluma B, Svahn CM, Ron D. Differential effect of cell-associated heparan sulphates on the binding of keratinocyte growth factor (KGF) and acidic fibroblast growth factor to the KGF receptor. J Biol Chem. 1994;269:32279-85.
45. Pilia G, Hughes-Benzie RM, Mackenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A, Schlessinger D. Mutation in GPC3, a glypican gene, cause the Simpson-Globai- Behmel overgrowth syndrome. Nat Genet. 1996;12:241-7.
46. Sung YK, Hwang SY, park MK, Farooq M, Han IS, Kim JC, Kim M. Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci. 2003;94:259-62.
47. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppou T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;20:16-25.
48. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89-97.
49. Kaseb AO, Hanbali AH, Contant M, Hassan MM, Wollner I, Philip PA. Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer. 2009;115:4895-906.
50. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219: 983-5.
51. Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, Zou L. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int. 2005;4: 544-9.
52. Poon RT, Ho JW, Tong CS, Lau C, Ng IO, Fan ST. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg. 2004;91:1354-458.
53. Li X, Feng GS, Zheng CS, Zhuo CK, Liu X. Expression of plasma vascular endothelial growth in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level. World J Gastroenterol. 2004;10:2878-82.
54. Suzuki H, Mori M, Kawaguchi C, Adachi M, Miura S, Ishii H. Serum vascular endothelial growth factor in the course of transcatheter arterial embolization of hepatocellular carcinoma. Int J Oncol. 1999;14:1087-90.
55. Xiong ZP, Yang SR, Liang ZY, Xiao EH, Yu XP, Zhou SK, Zhang ZS. Association between vascular endothelial growth factor and metastasis after transcatheter chemoembolization in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2004;3:386-90.
56. Poon RT, Lau C, Pang R, Ng KK, Yuen J, Fan ST. High serum vascular endothelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol. 2007;14:1835-45.
57. Verrcchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118: 211-5.
58. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human diseases. N Engl J Med. 2000;342: 1350-8.
59. Pasche B. Role of transforming growth factor beta in cancer. J Cell Physiol. 2001;186:153-68.
60. Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology. 2001;34:859-67.
61. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev. 2001;20:133-43.
62. Yao D-F, Dong Z-Z, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6: 241-7.
63. Erlitzki R, Minuk GY. Telomeres, telomerase and HCC: the long and the short of it. J Hepatol. 1999;31:939-45.
64. Nakashiro R, Kitamoto M, Tahara H, Nakanishi T, Ide T, Kajiyama G. Significance of telomerase activity in the diagnosis of small differentiated hepatocellular carcinoma. Int J Cancer. 1997; 74:141-7.
65. Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res. 1999;5:1961-5.
66. Miura N, Meda Y, Kanbe T, Yazama H, Takeda Y, Sato R, Tsukamoto T, Sato E, Marumoto A, Harada T, Sano A, Kishimoto Y, Hirooka Y, Murawaki Y, Hasegawa J, Shiota G. Serum telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res. 2005;11:3205-9.
67. Miura N, Osaki Y, Nagashima M, Kohno M, Yorozu K, Shomori K, kanbe T, Oyama K, Kishimoto Y, Maruyama S, Noma E, Horie Y, Kudo M, Sakaguchi S, Hirooka Y, Ito H, Kawasaki H, Hasegawa J, Shiota G. A novel biomarker TERT mRNA is applicable for early detection of hepatoma. BMC Gastroenterol. 2010;10:46.
68. Ikeda H, Tateishi R, Enooku K, Yoshida H, Hayato N, Masuzaki R, Kondo Y, Tadashi Goto Y, Shiina S, Kume Y, Tomiya T, Inoue Y, Nishikawa T, Ohtomo N, Tanoue Y, Ono T, Koike K, Yatomi Y. Prediction of hepatocellular carcinoma development by plasma ADAM13 in chronic hepatitis B and C. Cancer Epidemiol Biomarkers Prev. 2011;20:2204-11.
69. Qui J, Huang P, Liu Q, Hong J, Li B, Lu C, Wang L, Wang J, Yuan Y. Identification of MACC1 as a novel prognostic marker in hepatocellular carcinoma. J Transl Med. 2011;9:166.
70. Qi P, Cheng S, wang H, Li N, Chen Y, Gao C. Serum microRNA as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS ONE. 2011;6: e28486.
71. Miyahara K, Nouso K, Tomoda T, Kobayashi S, Hagihara H, Kuwaki K, Toshimori J, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, takai A, Yamamoto K. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26:1604-11.
72. Makridakis M, Vlahou A. Secretome proteomics for discovery of cancer biomarkers. J Proteomics. 2010;73:2291-305.